Are you attending AAIC? If so, while there, network with Bioclinica representatives to learn more about our readily available global network of investigator sites and our leading medical imaging and molecular marker lab services.
Meet with Bioclinica to:
- Discuss recruitment best practices for AD clinical trials.
- Review optimal infrastructure required to conduct large prescreening programs and to execute protocols of prodromal Alzheimer's disease/mild cognitive impairment clinical trials.
- Learn how Bioclinica CSF or blood-based biomarkers can advance your AD drug development program
- Understand why Sponsors of critical Phase III AD studies with imaging endpoints overwhelmingly rely on Bioclinica's neuroscience team
Bioclinica Posters at AAIC 2016
With more experience in the design and conduct of neuroimaging clinical trials than any other imaging core lab, Bioclinica's Neuroscience team will lead several poster sessions during this year's AAIC.
ASSESSING REGIONAL CORTICAL THICKNESS FOR PREDICTING MCI CONVERSION TO AD
Joel Schaerer, et al
Sat, Jul 23, 12:15 – 2:00 PM
Wed Jul 27, 12:00- 1:00 PM
Relationship between volumetric MRI parameters, APOE4 and MMSE status at baseline in Verubecestat (MK-8931) mild-to-moderate Alzheimer's disease patient trial
Cyrille Sur, et al
Mon Jul 25, 9:30-10:30 AM
Low Prevalence of Amyloid Positivity in Healthy Elderly Participants of a Methodology Study Evaluating Remote Tablet-Based Cognitive Learning
Claire Leurent, et al
Wed July 27, 9:30 – 10:30 AM
Does Regional Amyloid Burden Impact Domain-Specific Cognitive Impairment?
Tiffani Voss, et al
Wed July 27, 9:30 -10:30 AM
Head-to-Head Comparison of Image Analysis Methods in Longitudinal Alzheimer's disease FDG PET Studies
Gregory Klein, et al
Wed, July 27, 1:00 PM - 2:00 PM